Sita Swamy, APRN
Adult Health · Orlando, FLNPI 1518257914
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Alnylam Pharmaceuticals Inc. accounts for 77.3% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $25,974, more than ten times the $1,399 reported in 2021. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $215.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$38K
- Pfizer$4K
- Medtronic$2K
- United Therapeutics Corporation$1K
- Abbott$717
- Actelion Pharmaceuticals US, Inc.$679
- plus $3K from 15 others
What the payments were for
- Consulting fees$7201%
- Speaking & faculty fees$25,59653%
- Travel & lodging$12,72126%
- Food & beverage$9,06119%
- Education$5051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 87 | $37,569 |
| Pfizer | 30 | $3,961 |
| Medtronic | 15 | $1,548 |
| United Therapeutics Corporation | 12 | $1,074 |
| Abbott | 10 | $717 |
| Actelion Pharmaceuticals US, Inc. | 11 | $679 |
| AstraZeneca | 10 | $455 |
| Impulse Dynamics (USA) Inc. | 6 | $445 |
| Boehringer Ingelheim | 13 | $359 |
| Boston Scientific | 2 | $256 |
| Novo Nordisk | 3 | $252 |
| Kestra Medical Technology Services, Inc. | 1 | $214 |
| Abiomed | 2 | $209 |
| Cvrx, Inc. | 3 | $205 |
| Novartis | 5 | $162 |
| Scpharmaceuticals Inc. | 9 | $161 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $102 |
| Merck | 3 | $61 |
| Bridgebio Pharma, Inc. | 1 | $37 |
| Bayer | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$34,396
- VYNDAQEL$2,650
- VYNDAMAX$975
- OPTIMIZER$689
- ORENITRAM$372
- ONPATTRO$351
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$243
- Assure WCD$214
- HeartMate 3 Left Ventricular Assist Device$200
- Impella$184
- LUX-Dx Insertable Cardiac Monitor$172
- LINQ II$163
- Barostim Neo System$162
- FARXIGA$135
- UPTRAVI$135
- OPSUMIT$135
- TYVASO$125
- CAMZYOS$115
- Wegovy$114
- LifeVest$102
How this compares
$48,603 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 369 | $8,228,378 |
| AmvuttraVutrisiran Sodium | 17 | $1,981,085 |
| VyndaqelTafamidis Meglumine | 30 | $629,369 |
| EntrestoSacubitril/Valsartan | 192 | $267,021 |
| JardianceEmpagliflozin | 148 | $203,463 |
| OzempicSemaglutide | 73 | $76,094 |
| EliquisApixaban | 73 | $73,830 |
| FarxigaDapagliflozin Propanediol | 45 | $55,067 |
| Torsemide | 132 | $4,131 |
| Metoprolol Succinate | 147 | $2,021 |
| Spironolactone | 194 | $1,652 |
| Bisoprolol Fumarate | 36 | $1,278 |
| Megestrol Acetate | 19 | $1,175 |
| Potassium Chloride | 52 | $789 |
| Bumetanide | 18 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $3,961 | $8,931,577472 claims |
| Alnylam Pharmaceuticals Inc.Amvuttra | $37,569 | $1,981,08517 claims |
| NovartisEntresto | $162 | $267,021192 claims |
| Boehringer IngelheimJardiance | $359 | $203,463148 claims |
| Novo NordiskOzempic | $252 | $76,09473 claims |
| AstraZenecaFarxiga | $455 | $55,06745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Orlando
- Andreina NeallOrlando$16K
- Jessica SettineriOrlando$14K
- Kristen KessingerOrlando$13K
- Angelo LewisOrlando$12K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.